



Communiqué

Contact us for more
information or to sign up
for an eBulletin alert:

Website:
www.pmprb-cepmb.gc.ca

Twitter: [@PMPRB_CEPMB](https://twitter.com/PMPRB_CEPMB)

Phone: 1-877-861-2350
TTY: 613-957-4373

Email:
pmprb@pmprb-cepmb.gc.ca

2011 Annual Report of the PMPRB Released

OTTAWA, June 21, 2012 – The Honourable Leona Aglukkaq, Minister of Health, tabled the 2011 Annual Report of the Patented Medicine Prices Review Board (PMPRB) with the Clerks of the House of Commons and the Senate on June 20, 2012.

The report provides detailed information on the PMPRB's regulatory activities, patentees' compliance with the Board's price Guidelines, sales and price trends of patented drugs in Canada, including international price comparisons, and spending on pharmaceutical R&D.

The PMPRB reports that sales of patented drug products increased from \$12.9 billion in 2010 to \$13.1 billion.

Prices of patented drug products sold by patentees, as measured by the Patented Medicines Price Index, remained on average unchanged while the Consumer Price Index rose by 2.9%. Canadian prices were the fourth highest among the seven comparator countries, lower than prices in Switzerland, Germany and the United States.

Patentees reported 109 new patented drug products to the PMPRB in 2011. A total of 1,282 patented drug products for human use were under the PMPRB's jurisdiction in 2011.

While the vast majority of prices remained within the Board's Guidelines, the Chairperson approved 15 Voluntary Compliance Undertakings in 2011 to the end of May 2012. The Board completed three price hearings. A decision on the merits is pending in one matter, Sandoz Canada Inc., and two proceedings are ongoing, Apotex Inc. (jurisdiction) and Apo-Salvent CFC-Free. In addition to price reductions, excess revenues totalling \$24 million were offset by way of payments to the Government of Canada through VCUs and Board Orders in 2011 up to May 31, 2012.

The trend in R&D continued in 2011. Patentees reported total R&D expenditures of \$991.7 million, a decline of 15.8% over 2010, while members of Rx&D (Canada's Research-Based Pharmaceutical Companies) reported \$901.2 million, a decline of 9.9%. The R&D-to-sales ratios declined from 6.9% in 2010 to 5.6% for all patentees, and from 8.2% to 6.7% for Rx&D members.

The PMPRB's mandate is to ensure that prices at which patentees sell their patented medicines in Canada to wholesalers, hospitals and pharmacies are not excessive; and, to report on pharmaceutical trends and R&D expenditures by pharmaceutical patentees.

Reference: Marie-Christine Lalonde, Media Relations
Tel: 613-960-4551; Toll-Free: 1-877-861-2350
E-mail: marie-christine.lalonde@pmprb-cepmb.gc.ca